Vaishali Pharma gets registration for 3 products in Myanmar

Vaishali Pharma Limited has received a registration for three products including VMOX CV-1200, VMOX CV-600, and CYBUFIN-1,500 in Myanmar market. These products have a good demand in the local market of Myanmar.

These products are in the form of an injection while, their therapeutic usage is antibiotic.

This remarkable achievement in Myanmar market symbolises a landmark enabling the company to reach out more and strengthen its presence in the high growth market of Myanmar. This would also enable it to reach out to more and more territories to strengthen its presence in the key markets of the surrounding regions.

The company has more than 120 formulation brands being marketed in multiple countries; with dossier in CTD/ACTD format along with its respective bioequivalence. It has abided by the norms of extending uncompromised quality products and has raised the standards of the industry time and again.

Vaishali Pharma Ltd is a globally well-trusted brand with high quality products, accepted by companies across the globe. The company is amongst a leading player in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally.

On Thursday, the stock of Vaishali Pharma opened at Rs 52.40, up by 1.2 per cent on NSE. In the last week of January 2020, the company hit both, 52-week high and low of Rs 57.75 and Rs 46.15, respectively.